Dynatronics (DYNT) a leading manufacturer of health and therapy products announced that it has landed an extension of its subsidiary Bird & Cronin renewed key distribution agreement with Intalere, a leading group purchasing organization in the health care industry.
This renewed agreement extends the partnership to 2024, the two companies has been Intalere preferred provider for over 20 years supporting growth and the mission to elevate patient’s healthcare.
Bird & Cronin offers high quality products to meet the changing needs of the health care industry, with the agreement in place members of Intalere will receive negotiated pricing on a wide variety of bracing solutions which includes cervical and abdominal to knees, ankles, heels, arms, and wrist.
Many analysts predict that with the ramping up of COVID-19, the slowdown in elective procedures could show a sign of reversal, brining a need of increased rehab products.
Don't Miss The Next Big Story
Join our free mailing list below to receive real-time news alerts and our next featured stock!What to consider if you buy DYNT stock
Before you think about buying some DYNT stock, you will have to accept some risks involved, here are some you need to consider:
- Dynatronics is not profitable yet, the company must rely on money in the bank to keep its operations going. They may raise funds through public markets which may lead to shareholder dilution.
- DYNT is a penny stock (under $5) which may experience high levels of volatility.
Dynatronics is one of the top moving gainers in the market along with Pandion Therapeutics which has just been acquired by Merk for a 134% premium.
Bottom line
There are always risks when investing however, I think that Dynatronics looks like a promising long-term investment. The renewed agreement with Inalere will certainly help the company reach its goal of becoming profitable. I recommend adding DYNT stock to your watchlist.
